ONO Pharmaceutical Co ((OPHLF)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ono Pharmaceutical Co. Ltd is conducting a Phase I clinical study titled ‘An Open-label, Multi-center, Non-randomized Phase I Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ONO-4685 Given as Monotherapy in Patients With Relapsed or Refractory T Cell Lymphoma.’ The study aims to evaluate the safety and initial effectiveness of ONO-4685, a drug administered to patients with challenging T cell lymphoma cases.
The intervention being tested is ONO-4685, an experimental drug delivered via IV infusion. It is designed to treat patients with relapsed or refractory T cell lymphoma by continuing administration until disease progression or unacceptable toxicity occurs.
This interventional study follows a single-group assignment model without randomization or masking, focusing primarily on treatment. The study’s main goal is to assess the therapeutic potential of ONO-4685 in a targeted patient group.
The study began on September 30, 2021, with an estimated primary completion date yet to be announced. The latest update was submitted on June 1, 2025, indicating ongoing recruitment and study progress.
The progress of this study could significantly influence Ono Pharmaceutical’s stock performance by potentially enhancing investor confidence if ONO-4685 shows promising results. The competitive landscape in oncology treatments may also shift, depending on the outcomes of this study.
The study is currently recruiting, with further details available on the ClinicalTrials portal.